Polysubstance Use in Pregnancy: Surveillance, Interventions, and Next Steps.

Autor: Park Y; National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, Tennessee, USA., Dang EP; National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Board A; National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Gilboa SM; National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Ondersma SJ; Department of Public Health, Michigan State University, East Lansing, Michigan, USA., Smid MC; Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah, USA., Shakib JH; Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA., Mitchell KT; FASD United, Washington, D.C., USA., England LJ; National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Broussard CS; National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Meaney-Delman D; National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Iskander J; Office of Science, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Kim SY; National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jazyk: angličtina
Zdroj: Journal of women's health (2002) [J Womens Health (Larchmt)] 2023 Sep; Vol. 32 (9), pp. 899-904. Date of Electronic Publication: 2023 Aug 08.
DOI: 10.1089/jwh.2023.0341
Abstrakt: Substance use during pregnancy increases risk for a wide range of adverse maternal and neonatal health outcomes. Polysubstance use is common among people who use substances during pregnancy; however, the risks of combined substance exposures during pregnancy are poorly understood. In this report, we provide an overview of the activities of the Centers for Disease Control and Prevention (CDC) and partners and identified gaps related to (1) surveillance, (2) routine screening, and (3) prevention of polysubstance use during pregnancy. Efforts by CDC and other partners to reduce polysubstance use during pregnancy can improve the health of pregnant people and their infants and children.
Databáze: MEDLINE